VIENNA — For patients with non-small cell lung cancer (NSCLC) carrying the specific T790M mutation in the epidermal growth factor receptor (EGFR) gene, there is now a new standard of care, say experts ...

Treatment for EGFR-Sensitive Mutation NSCLCNumerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib ...

The study offers guidance to clinicians treating the roughly 10% of patients with rare EGFR mutations. Patients with non–small cell lung cancer (NSCLC) who have uncommon EGFR mutations appear to have ...

Eligible patients had EGFR mutations (T790M or rare activating) and received osimertinib 80 mg once daily. Patients with lung cancer with EGFR T790M were excluded. The primary end point was objective ...

Sixty-three patients with advanced EGFR-mutant lung cancer at 7 Canadian centers, who were being screened for the ASTRIS trial (ClinicalTrials.gov identifier: NCT02474355), participated in this ...

Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for ...